W J Mullally F J Cooke I M Crosbie S Kumar V E Abernethy E J Jordan M O'Connor A M Horgan R Landers J Naidoo P M Calvert
10.3389/fimmu.2022.871217
Front Immunol
2022 Apr 20;13:871217.
combination checkpoint inhibitors hematological adverse events ipilimumab nivolumab thrombotic-thrombocytopenic purpura
CC BY
https://pubmed.ncbi.nlm.nih.gov/35514990/
Melanoma / drug therapy Neoplasms, Second Primary Purpura, Thrombocytopenic, Idiopathic Purpura, Thrombotic Thrombocytopenic / diagnosis
Melanoma / drug therapy Neoplasms, Second Primary Purpura, Thrombocytopenic, Idiopathic Purpura, Thrombotic Thrombocytopenic / diagnosis Case Reports Humans Immunologic Factors Immunotherapy Ipilimumab / adverse effects Male Nivolumab / adverse effects Immunologic Factors Ipilimumab Nivolumab
PMC9067158
35514990
Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma
2022